Silvia Mccoll Wealth Management LLC Sells 250 Shares of Merck & Co., Inc. $MRK

Silvia Mccoll Wealth Management LLC lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 5.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,975 shares of the company’s stock after selling 250 shares during the quarter. Silvia Mccoll Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $315,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of MRK. Charles Schwab Investment Management Inc. lifted its position in Merck & Co., Inc. by 144.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company’s stock valued at $4,418,820,000 after purchasing an additional 29,104,112 shares during the last quarter. Nuveen LLC bought a new stake in shares of Merck & Co., Inc. in the 1st quarter worth about $991,553,000. Pacer Advisors Inc. lifted its holdings in shares of Merck & Co., Inc. by 2,240.9% in the 1st quarter. Pacer Advisors Inc. now owns 5,286,801 shares of the company’s stock worth $474,543,000 after acquiring an additional 5,060,959 shares during the last quarter. Amundi lifted its holdings in shares of Merck & Co., Inc. by 37.1% in the 1st quarter. Amundi now owns 13,077,716 shares of the company’s stock worth $1,130,397,000 after acquiring an additional 3,542,036 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth about $258,267,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.3%

MRK stock opened at $89.25 on Friday. The company has a market capitalization of $222.93 billion, a PE ratio of 13.75, a P/E/G ratio of 0.92 and a beta of 0.37. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $111.58. The firm’s 50-day moving average is $82.87 and its 200 day moving average is $81.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The company had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be given a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 3.6%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 49.92%.

Analysts Set New Price Targets

Several research firms have recently issued reports on MRK. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Wells Fargo & Company lowered their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $106.41.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.